StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $88.49 | $89.97 | +1.67% | 0.4M |
| 05-19 | $90.04 | $90.44 | +0.44% | 0.4M |
| 05-20 | $90.43 | $91.49 | +1.17% | 0.4M |
| 05-21 | $90.40 | $90.00 | -0.44% | 0.5M |
| 05-22 | $90.00 | $89.28 | -0.80% | 0.4M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q2 2026 2026-04-03 | Annual 2025 2025-12-31 | Q3 2025 2025-09-26 | Q2 2025 2025-06-27 |
|---|---|---|---|---|
Revenue | $439.58M | $1.85B | $1.38B | $913.89M |
Operating Income | $31.87M | $221.26M | $165.33M | $108.89M |
Net Income | $16.51M | $102.81M | $54.20M | $14.52M |
EPS (Diluted) | $0.48 | $2.89 | $1.52 | $0.41 |
Total Assets | $3.41B | $3.41B | $3.40B | $3.37B |
Total Liabilities | $1.71B | $1.66B | $1.65B | $1.67B |
Cash & Equivalents | $8.12M | $17.16M | $58.94M | $23.14M |
Free Cash Flow OCF − CapEx | $737.00K | $105.12M | $77.18M | $30.92M |
Shares Outstanding | 33.95M | 34.35M | 35.04M | 35.03M |
ITGR is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.